Board summary
Key figures
22,507
Registered population
62.7% aged 18–64
10.1%
Aged 65+
ICB 14.9% · England 17.9%
97.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~15,824
Core20 residents (est.)
Resident basis; registered basis ~22,012 · see page 3
2,693
Hypertension register
+5.89% in 3 yrs · England +5.60%
297
SMI register
9.5% of Rochdale (LAD)'s
402
COPD register
Reviews +9.86% in 3 yrs
Forecast to 2030
2,971
Hypertension patients, 2030
+278 on today
80.7%
QRISK ≥20% on statins, 2030
+1.37pp over 3 yrs
2.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Learning disability register fell over three years.
Recorded learning disability prevalence changed by -8.6% over 2023 to 2025 (Rochdale -15.8%, ICB +1.1%, England +5.4%), which could reflect unverified coding changes.
Breast and cervical screening trail benchmarks.
Breast screening is 59.5% (Rochdale 69.0%, ICB 68.8%, England 69.9%) and cervical screening is 62.6% (England 66.8%), which may reflect unverified access barriers.
Lipid therapy and SMI checks exceed England.
Lipid-lowering therapy for QRISK ≥ 20% reaches 77.8% (Rochdale 68.3%, ICB 67.0%, England 63.6%), and SMI blood pressure checks reach 86.3% (England 83.4%).
Population, age and ethnicity
A young population with 10.1% aged 65+ may explain low crude dementia prevalence
The Bridge PCN has a markedly young registered list of 22,507 patients: 27.2% (6,131) are aged 0-17, compared with 23.5% in Rochdale, 21.8% in NHS Greater Manchester ICB and 19.6% in England. Conversely, only 10.1% (2,261) are aged 65+, below Rochdale (14.7%), NHS Greater Manchester ICB (14.9%) and England (17.9%). The 18-64 cohort accounts for 62.7% (14,115). Census estimates record 0.1% Gypsy or Irish Traveller and 0.1% Roma. Lower crude dementia prevalence of 0.4% (102 patients; Rochdale 0.8%, England 0.8%) is consistent with this young structure, though benchmark scenarios indicate an unadjusted 74-patient gap.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Rochdale (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Rochdale LA) | 2,300 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 74.7% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 53.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Rochdale LA) | 1,088 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Rochdale LA) | 19.0 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 covers 97.2% of registered patients, spanning from 92.1% to 100.0% across practices
Average IMD decile is 1.8 (Rochdale 3.6, England 5.5). Core20 quintile 1 covers 97.2% of registered patients, exceeding Rochdale (48.0%) and England (21.0%). Across practices, Core20 shares span a 7.9 pp range: Dr Gwd Bhima is 100.0% and Family Practice is 92.1%. Estimated resident Core20 population is 15,824, whereas practice estimates sum to 22,012 registered patients on different denominator bases. Reconciling registered patient lists with resident small-area counts is required before deploying targeted outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
297
SMI register
1.29% recorded prevalence
147
Learning disability register
0.64% recorded prevalence
11
Care homes, 262 beds
In the PCN catchment
9.7%
Provide unpaid care
Rochdale (LAD), Census 2021
Severe mental illness recorded prevalence is 1.3% (297 patients), above Rochdale (1.2%) and England (1.0%). Learning disability prevalence is 0.6% (147 patients; Rochdale 0.7%, England 0.6%). The PCN catchment contains 11 care homes with 262 beds; bed capacity does not establish resident occupancy. Higher severe mental illness prevalence makes maintaining annual health check coverage a workload priority.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.3% (England 1.0%). Annual checks reach 86.3% for blood pressure and 85.4% for BMI (England 83.4% and 82.1%). However, blood pressure review completion is 78.8% at Croft Shifa Health Centre.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
2,693
Hypertension register
+5.89%
Register growth, 3 yrs
Rochdale (LAD) +6.17% · England +5.60%
+6.90pp
BP control, under 80
≤140/90 · −0.27pp aged 80+
+278
More patients by 2030
Forecast 2,971 (13.12%)
Hypertension case-finding and control
Hypertension prevalence is 11.7% (2,693 patients), compared with England (15.2%), Rochdale (15.6%) and NHS Greater Manchester Integrated Care Board (14.4%). Hypertensive patients treated to target improved +15.1% over 2023 to 2025 (England +3.6%), with current control at 67.9% (England 70.3%, Rochdale 70.5%). Recent blood pressure checks reached 87.3% (England 90.0%). For patients aged 80 and over, blood pressure control is 81.1% (England 81.2%), changing -0.3% over 2023 to 2025 (England +2.2%). With blood pressure recording and older-adult control trailing national benchmarks, systematic recall for patients aged 80 and over could improve management.
Lipids and statins
Lipid-lowering therapy uptake in QRISK ≥ 20% reaches 77.8%, exceeding Rochdale (68.3%), NHS Greater Manchester Integrated Care Board (67.0%) and England (63.6%). For patients with diabetes aged 40 and over without cardiovascular disease, statin treatment is 83.8% (England 73.2%, Rochdale 76.6%). Prescribing exceeds comparators across both cohorts.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 47,839 | £2.00 | £1.94 | £1.86 | £95,678 |
| Cardiovascular (all), 2025 | 51,933 | £3.02 | £3.15 | £3.33 | £156,838 |
In 2026, the PCN prescribed 47,839 items for lipid-regulating drugs at £2.00 per item (England £1.86, Rochdale £2.08, NHS Greater Manchester Integrated Care Board £1.94), spending £6,697 more than at England's unit cost across 47,839 items. Total spend was £95,678. Unit cost is a cost indicator rather than an efficiency target.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+17.92%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.43%
Asthma prevalence, PCN 3-yr % change
COPD prevalence changed +20.0% over 2023 to 2025 (England +2.6%) to 1.8% (402 patients), with 78.6% reviewed (England 76.4%), leaving an unadjusted register gap range of +24 to +183 patients. Asthma prevalence is 6.8% (1,447 patients; England 6.6%) with 68.2% reviewed (England 65.7%), leaving about 460 patients without a recorded review. Second-hand smoke recording for ages 6-19 reaches 87.8% (296 patients; England 78.8%). Asthma prescribing for ages 5-19 is 1,262 items per 1,000 (Rochdale 1,888, England 1,488).
Cancer register and children's immunisation
Cancer prevalence is 2.0% (455 patients), below England (3.8%) and Rochdale (3.6%). In Q1 2025/26, 12-month 6-in-1 coverage was 97.3% (95.0% target). However, 24-month MMR dose 1 (92.0%) and age-5 4-in-1 booster (92.0%) trail target by 3 pp, with age-5 MMR dose 2 at 93.3%. Closing pre-school immunization gaps requires targeted recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In NHS Greater Manchester ICB (2022), 55.6% of staged cancers (6,491 of 11,679 with known stage; 70.8% known-stage share) were diagnosed at stage 1 or 2, in line with England (55.3%) but 19.4 pp below the 75.0% national ambition, representing 2,268.2 extra cases. ICB staging reflects wider system data, not PCN performance, and is subject to known-stage coverage. In primary care, PCN cervical screening coverage is 62.6% (England 66.8%; Rochdale 68.8%), and breast screening coverage is 59.5% (England 69.9%). Lower screening uptake may delay early cancer detection, making proactive recall and targeted outreach key operational priorities.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For Northern Care Alliance NHS Foundation Trust in Jul 2026, 62-day cancer referral to treatment was 78.6% (standard 85.0%), above Manchester University NHS Foundation Trust (72.8%), NHS Greater Manchester Integrated Care Board (75.7%) and England (71.2%). The 28-day faster diagnosis standard reached 75.2% (standard 75.0%), behind Manchester University NHS Foundation Trust (80.1%), the ICB (79.5%) and England (79.3%). Diagnostic 6+ week waits were 5.1% for MRI and 4.1% for CT, but 31.5% for echocardiography and 38.2% for audiology. These acute provider figures describe system pathway flow, not PCN performance.
| Pathways within standard (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 82.48 | 80.06 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 96.25 | 92.54 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 76.77 | 72.85 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Tameside and Glossop Integrated Care | Manchester | England |
|---|---|---|---|---|
| MRI | 5.09 | 0.00 | 11.68 | 21.40 |
| CT | 4.10 | 0.18 | 14.66 | 9.92 |
| Echocardiography | 31.48 | 0.00 | 4.91 | 28.48 |
| Colonoscopy | 40.04 | 1.51 | 4.51 | 30.83 |
| Gastroscopy | 36.48 | 5.45 | 29.35 | 29.02 |
| All 15 DM01 tests | 15.71 | 0.80 | 8.98 | 23.14 |
| Community services activity | Rochdale residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 60,250 | 573,310 |
| Referrals | 9,455 | 94,470 |
| Patients with a contact | 19,345 | 183,535 |
Community services (residents of Rochdale), Jun 2026 (provisional). In Jun 2026 (provisional), 40.9% of community service contacts among Rochdale borough residents (24,650 of 60,250 contacts) were with adults aged 65+. While these figures capture borough-level activity rather than PCN-specific referrals, they reflect substantial community service dependency among older residents across the wider local health economy.
Practice variation and patient experience
Practice variation and patient experience
Overall QOF achievement across England is 92.5%. Practice achievement across the PCN ranges from 83.3% at Croft Shifa Health Centre to 96.6% at Dr Mb Ghafoor & Partners (Family Practice achieved 93.3%). QOF vaccination achievement spans 56.7 pp, from 38.6% at The Dale Medical Practice to 95.4% at Dr Mb Ghafoor & Partners (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Dr Gwd Bhima | 84 | 100.0 | 87.3% | 82.8% | 96.2% |
| Family Practice | 128 | 92.1 | 90.1% | 73.4% | 88.1% |
| Dale Medical | 93 | 100.0 | 70.7% | 83.9% | 76.5% |
| Dr Mb Ghafoor & | 89 | 97.6 | 52.3% | 86.3% | 67.5% |
| Croft Shifa | 112 | 100.0 | 24.5% | 72.3% | 44.9% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Seven of 25 measures trail England, led by learning disability prevalence falling 8.6%
Across 25 compared measures, 7 trailed England's change. Over 2023 to 2025, learning disability QOF prevalence fell 8.6% (England +5.4%; Rochdale -15.8%), heart failure reviews rose +3.4% (England +8.7%), and QRISK ≥ 20% statin therapy rose +1.8% (England +6.2%). Relative improvements outpaced national rates in asthma reviews (+17.9% vs +4.4% England), hypertension control (+15.1% vs +3.6%), and 2023 to 2024 breast screening (+21.3% vs +8.4%). Severe mental illness blood pressure checks rose +13.4 pp (England +4.4 pp) and BMI checks rose +14.3 pp (England +5.1 pp).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
Heart failure reviews
QRISK statin treatment
Cervical screening
BP control, 80+
Asthma reviews
Breast screening (53-70)
Hypertension treated to target
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Rochdale (LAD) | Asset | PCN | Rochdale (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 11 (262 beds) | n/a | Schools (catchment) | 64 | n/a |
| Children's centres | 7 | 17 | Places of worship | 39 | 116 |
| Libraries | 1 | 12 | Primary schools (LA maintained) | 9 | 38 |
| Primary academies | 8 | 26 | Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
On the 1,447-patient asthma register, 68.2% had a review in the last 12 months (England 65.7%, Rochdale 66.2%), leaving a scale indicator of about 460 patients without a recorded review. For discussion, practices could run a single-template asthma recall offering flexible after-school or holiday slots alongside inhaler prescribing checks. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Age-stratified COPD case-finding search
COPD QOF prevalence is 1.8% (402 patients) vs 2.6% in Rochdale and 1.9% in England, giving an unadjusted benchmark register gap range of +24 to +183 patients. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Learning disability register validation audit
Learning disability QOF prevalence fell 8.6% over 2023 to 2025 (England +5.4%, ICB +1.1%, Rochdale -15.8%); current prevalence is 0.6% (147 patients), with an unadjusted benchmark gap range of -15 to +1. Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Age-stratified dementia audit (p2) | Dementia: QOF prevalence | 66.7% diagnosis ambition · 95% care plan 2027 | PCN |
| Core20 population reconciliation (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI blood pressure recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Older adult hypertension recall (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation call recall (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Age-stratified COPD case-finding search (p12) | COPD register · COPD: QOF prevalence · Aged 65+ | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Learning disability register validation audit (p12) | Learning disability register · Learning disability: QOF prevalence | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
